Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Convalescent serum lines up as first-choice treatment for coronavirus

1 May 2020

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32358594
DOI: 10.1038/d41587-020-00011-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Convalescent serum lines up as first-choice treatment for coronavirusPMID 32358594Read ↗

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal AntibodiesSemantic proximity Read ↗

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide EvidenceSemantic proximity Read ↗

SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantationSemantic proximity Read ↗

COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic reviewSemantic proximity Read ↗

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity Read ↗

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacySemantic proximity Read ↗

Convalescent plasma therapy in immunocompromised patients infected with the BA.1 or BA.2 Omicron SARS-CoV-2Semantic proximity Read ↗

Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.Semantic proximity Read ↗

Treatment of COVID-19 Patients with Convalescent Plasma in Houston, TexasSemantic proximity Read ↗

A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19Semantic proximity Read ↗

Outcomes of Convalescent Plasma with Defined High- Versus Lower-Neutralizing Antibody Titers Against SARS-CoV-2 Among Hospitalized Patients: Coronavirus Inactivating Plasma (CoVIP), Double-Blind Phase 2 StudySemantic proximity Read ↗

China approves first homegrown COVID antiviralSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.